Human epidermal growth factor receptor 2 (HER2) is overexpressed or amplified in nearly 20% of BC cases and is an FDA-approved predictive marker to identify responders to anti-HER2 agents [2]. This evidence concerns the gene ERBB2 and breast cancer.